Compare · BLFS vs MASI
BLFS vs MASI
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.42B, about 5.2x BLFS ($1.82B).
- BLFS has hit the wire 6 times in the past 4 weeks while MASI has been quiet.
- MASI has more recent analyst coverage (24 ratings vs 9 for BLFS).
- Company
- BioLife Solutions Inc.
- Masimo Corporation
- Price
- -
- -
- Market cap
- $1.82B
- $9.42B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 6
- 0
- Recent ratings
- 9
- 24
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest BLFS
- BioLife Solutions downgraded by The Benchmark Company
- SEC Form 10-Q filed by BioLife Solutions Inc.
- BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BioLife Solutions Reports Second Quarter 2026 Financial Results
- SEC Form 425 filed by BioLife Solutions Inc.
- BioLife Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 425 filed by BioLife Solutions Inc.
- BioLife Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 425 filed by BioLife Solutions Inc.
- Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Latest MASI
- SEC Form 15-12G filed by Masimo Corporation
- Director Solomon Darlene J. S. returned $542,700 worth of shares to the company (3,015 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- Director Scannell Timothy J returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- Director Lane Wendy E returned $469,440 worth of shares to the company (2,608 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director by deputization Politan Capital Management Lp
- Director by deputization Politan Capital Management Lp returned $826,357,140 worth of shares to the company (4,590,873 units at $180.00) (SEC Form 4)
- Chairman of the Board Brennan Michelle returned $1,675,620 worth of shares to the company (9,309 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Accounting Officer Hataishi Paul returned $2,397,060 worth of shares to the company (13,317 units at $180.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Operations Sampath Anand returned $6,102,180 worth of shares to the company (33,901 units at $180.00), closing all direct ownership in the company (SEC Form 4) to cover taxes
- SEC Form 4 filed by Chief Commercial Officer Meehan Greg Allen (for tax liability)